The first 60 days: High-risk acute lymphoblastic leukaemia in children (high-risk B-ALL and T-ALL)
High-risk childhood leukaemia means a child aged ten or over, a very high white cell count, T-cell disease, spread to the brain or testes, or adverse genetics, and it is treated with longer and more intensive chemotherapy. Most children are still cured; the T-cell form gained the drug nelarabine after the AALL0434 trial, and cranial radiotherapy has been dropped for almost everyone. Below, week by week, is what OnCo's record of High-risk acute lymphoblastic leukaemia in children (high-risk B-ALL and T-ALL) says about the first two months: the order is typical, the timing is yours to ask about. Sections appear only where the record has something to say. Orientation, not medical advice.
What happens now
Staging tests establish exactly what and where the cancer is. Everything else follows from the answers.
Ask which of these were tested and what the results were; see the report reader for what each value means.
These specialties appear in the standard of care for this cancer. In most centres they meet weekly as a tumour board to agree each plan; you can ask when yours was discussed and what was decided.
- PathologistNamed in the standard of care for: Induction (four weeks), Very high risk: induction failure, hypodiploidy, persistent residual disease.
- Medical oncologistNamed in the standard of care for: Induction (four weeks), Consolidation and interim maintenance, high-risk B-ALL, T-cell ALL, Delayed intensification and maintenance and 1 more.
- Clinical oncologist (radiotherapy)Named in the standard of care for: T-cell ALL.
- Transplant and cell therapy teamNamed in the standard of care for: Consolidation and interim maintenance, high-risk B-ALL, Delayed intensification and maintenance, Very high risk: induction failure, hypodiploidy, persistent residual disease.
- Palliative and supportive care teamNamed in the standard of care for: Induction (four weeks), Delayed intensification and maintenance.
A second opinion from a centre that treats many similar cases is normal, not rude; the standard of care tells you what to compare it against.
Each row is a setting from the standard of care, in the order it usually arises. Not all will apply to you; your stage and biomarkers decide which do. The guideline grade, where recorded, says how strong the evidence is.
- 1.Very high risk: induction failure, hypodiploidy, persistent residual diseaseNCI PDQ: Childhood Acute Lymphoblastic Leukemia Treatment (health professional version)
Blinatumomab to clear residual disease, then allogeneic transplant in first remission; CD19 CAR T-cells as consolidation in trials.
- 2.Induction (four weeks)NCI PDQ: Childhood Acute Lymphoblastic Leukemia Treatment (health professional version)
Four-drug induction: vincristine, dexamethasone or prednisone, daunorubicin and pegylated asparaginase with intrathecal methotrexate; MRD at day 29.
Augmented BFM with Capizzi escalating methotrexate and nelarabine courses for intermediate- and high-risk disease (AALL0434); cranial irradiation only for CNS3 or the highest risk (AALL1231).
- 4.Consolidation and interim maintenance, high-risk B-ALLNCI PDQ: Childhood Acute Lymphoblastic Leukemia Treatment (health professional version)
Augmented BFM consolidation with cyclophosphamide, cytarabine, mercaptopurine and asparaginase; high-dose methotrexate with leucovorin rescue (AALL0232); blinatumomab or inotuzumab ozogamicin added in current trials.
- 5.Delayed intensification and maintenanceNCI PDQ: Childhood Acute Lymphoblastic Leukemia Treatment (health professional version)
Two delayed intensification blocks with vincristine, dexamethasone, doxorubicin, cyclophosphamide, cytarabine and thioguanine; maintenance with mercaptopurine, methotrexate and vincristine-steroid pulses.
Generated from this cancer's standard of care, biomarkers and open problems. Take the group that matches where you are. To tick, add your own and print, open the one-page appointment sheet.
Newly diagnosed
- What is my exact diagnosis, stage, and grade, and which tests established them?Everything else follows from an accurate stage and subtype.
- Which biomarkers have been tested on my tumour (for example Age and white cell count, Immunophenotype, Karyotype and FISH, BCR::ABL1 and BCR::ABL1-like screening, Flow cytometry MRD at day 29 and end of consolidation), and what were the results?These results decide eligibility for targeted therapy, immunotherapy, and trials.
- Which subtype is my cancer, and does that change the recommended treatment?Recognised subtypes for this cancer include High-risk B-ALL by age or white count, B-ALL with adverse genetics, B-ALL with end-induction or end-consolidation residual disease.
- Is germline (inherited) genetic testing recommended for me or my family?Inherited variants can change treatment and matter for relatives.
Induction (four weeks)
- For my situation (induction (four weeks)), which of the standard options do you recommend and why?Guideline options include: Four-drug induction: vincristine, dexamethasone or prednisone, daunorubicin and pegylated asparaginase with intrathecal methotrexate; MRD at day 29.
- Am I a candidate for Vincristine, Dexamethasone, Prednisone or related drugs, and what side effects should I expect?Knowing the expected toxicities helps you plan work, family, and supportive care.
Consolidation and interim maintenance, high-risk B-ALL
- For my situation (consolidation and interim maintenance, high-risk b-all), which of the standard options do you recommend and why?Guideline options include: Augmented BFM consolidation with cyclophosphamide, cytarabine, mercaptopurine and asparaginase; high-dose methotrexate with leucovorin rescue (AALL0232); blinatumomab or inotuzumab ozogamicin added in current trials.
- Am I a candidate for Cyclophosphamide, Cytarabine, Mercaptopurine or related drugs, and what side effects should I expect?Knowing the expected toxicities helps you plan work, family, and supportive care.
T-cell ALL
- For my situation (t-cell all), which of the standard options do you recommend and why?Guideline options include: Augmented BFM with Capizzi escalating methotrexate and nelarabine courses for intermediate- and high-risk disease (AALL0434); cranial irradiation only for CNS3 or the highest risk (AALL1231).
- Am I a candidate for Nelarabine, Methotrexate, Asparaginase (pegaspargase, calaspargase pegol, Erwinia asparaginase), and what side effects should I expect?Knowing the expected toxicities helps you plan work, family, and supportive care.
Delayed intensification and maintenance
- For my situation (delayed intensification and maintenance), which of the standard options do you recommend and why?Guideline options include: Two delayed intensification blocks with vincristine, dexamethasone, doxorubicin, cyclophosphamide, cytarabine and thioguanine; maintenance with mercaptopurine, methotrexate and vincristine-steroid pulses.
- Am I a candidate for Vincristine, Dexamethasone, Doxorubicin or related drugs, and what side effects should I expect?Knowing the expected toxicities helps you plan work, family, and supportive care.
Very high risk: induction failure, hypodiploidy, persistent residual disease
- For my situation (very high risk: induction failure, hypodiploidy, persistent residual disease), which of the standard options do you recommend and why?Guideline options include: Blinatumomab to clear residual disease, then allogeneic transplant in first remission; CD19 CAR T-cells as consolidation in trials.
- Am I a candidate for Blinatumomab, Tisagenlecleucel, and what side effects should I expect?Knowing the expected toxicities helps you plan work, family, and supportive care.
Any stage
- Are there clinical trials I could join, for example of Inotuzumab ozogamicin, Blinatumomab, Tisagenlecleucel, Venetoclax?Trials are how the next standard of care is set; asking early keeps options open.
- Would a second opinion at a high-volume centre change anything, and can you help arrange it?Rare or high-stakes decisions benefit from a centre that treats many similar patients.
- What supportive care (symptom control, nutrition, exercise, mental health, financial help) is available from the start?Supportive care improves quality of life and helps patients complete treatment.
- I read that “No antibody or cell therapy target in routine use for T-ALL”. How does that affect my plan?Open problems are where trials and second opinions matter most.
- I read that “Which high-risk children still need transplant once immunotherapy clears residual disease”. How does that affect my plan?Open problems are where trials and second opinions matter most.
Trials open now for this cancer in OnCo, largest phase first. Joining a trial is a decision like any other: ask what the comparison arm is, whether a placebo is used, and what happens if you leave. The cancer page searches ClinicalTrials.gov live for more.
Much of what helps in the first weeks is free if you know to ask: testing, helplines, rides and lodging, second opinions, trial travel.
- High-risk acute lymphoblastic leukaemia in children (high-risk B-ALL and T-ALL): the full pageHigh-risk childhood leukaemia means a child aged ten or over, a very high white cell count, T-cell disease, spread to the brain or testes, or adverse genetics, and it is treated with longer and more intensive chemotherapy. Most children are still cured; the T-cell form gained the drug nelarabine after the AALL0434 trial, and cranial radiotherapy has been dropped for almost everyone.
- One-page appointment sheetYour questions, the words you may hear, what to bring, and space for the answers. Print it.
- Treatment sequencingWhich treatment tends to follow which, line by line.
- NavigatorStandard of care for your stage, what you have tried, and trials near you.
- Ph-like (BCR::ABL1-like) acute lymphoblastic leukaemia: Ph-like leukaemia has the gene-expression fingerprint of Philadelphia-positive leukaemia without the Philadelphia chromosome; behind it are dozens of kinase fusions and JAK pathway lesions, and finding which one is present tells doctors whether an imatinib-type drug or a JAK inhibitor might be added to chemotherapy.
- Event-free / disease-free survival (EFS, DFS, iDFS, RFS): In early-stage cancer: how long patients stay free of recurrence, progression, or death.
- B-ALL risk groups (NCI criteria, ETV6::RUNX1, hyperdiploidy, hypodiploidy, iAMP21, IKZF1, CNS status): Childhood leukaemia treatment is chosen from a risk table built over fifty years: age and white count at diagnosis (the NCI criteria), the chromosome pattern in the blasts (favourable ETV6::RUNX1 and high hyperdiploidy, unfavourable hypodiploidy, iAMP21, KMT2A, Ph-positive and Ph-like), whether leukaemia cells are in the spinal fluid, and above all how fast the leukaemia clears in the first month.
- Minimal / molecular residual disease (MRD): Cancer still present after treatment but too small to see on scans, detected by blood or marrow tests.
Every term links to the glossary.